Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 4/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | BCL6 | P41182 | 2/20 | 0.41 |
| ▸ | BCOR | Q6W2J9 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26087309 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNASIRT6KMT2AMEN1 | |
| SCHEMBL29851268 | 0.85 | ALDH1A1 (0.45) | ALDH1A1LMNASIRT6KMT2AMEN1 | |
| SCHEMBL521437 | 0.85 | ALDH1A1 (0.45) | ALDH1A1LMNASIRT6KMT2AMEN1 | |
| SCHEMBL29377558 | 0.84 | HRH3 (0.51) | ALDH1A1LMNAMAPTHRH3 | |
| SCHEMBL21814260 | 0.84 | HRH3 (0.51) | ALDH1A1LMNAMAPTHRH3 | |
| Hydrochloric Acid SCHEMBL382604 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNASIRT6KMT2AMEN1 | |
| SCHEMBL375364 | 0.84 | SIRT6 (0.57) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL29379635 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNASIRT6KMT2AMEN1 | |
| SCHEMBL29446151 | 0.84 | SIRT6 (0.57) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| SCHEMBL23092190 | 0.83 | BCL6 (0.40) | ALDH1A1LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALDH1A1 3512/4885LMNA 2407/4885SIRT6 4245/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALDH1A1 3512/4885LMNA 2407/4885SIRT6 4245/4885 |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | ALDH1A1 416/4885LMNA 1998/4885SIRT6 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.